Limnopharma named one of the 100 best startups of 2023

Limnopharma, specialized in the development of new therapies for various retinal diseases, has been named one of the 100 best startups of 2023 by the Spanish Association of Science and Technology Parks (APTE). The company focuses on the development of new treatments...

read more

Confirmation of Lim21 mechanism of action

As a result of the collaboration with Inoviem company, the direct interaction between lim21 and one target protein has been established. The identification of this target protein is in line with previous findings and corroborates a pathway involving activation of...

read more

LIM21 reaches the retina of pig eyes

Limnopharma’s team in collaboration with Prof. Alberto Zafra from the University of Granada has just carried out biodistribution experiments of LIM21 administered in eye drops in pigs. The animals were handled by expert veterinarians at IAVANTE, located in the Health...

read more

Covirán Group joins Limnopharma as investor

Covirán has formalized this week its direct participation in Limnopharma through a convertible note. From Limnopharma we thank the Covirán Group for its trust and support for our project, which represents a boost and allows us to continue working with the aim of...

read more

New therapies for retinal diseases.
Treatments for Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)


Edif Reina María,

Carretera Bailén-Motril, S/ N

Parc 102,

18210 Peligros, Granada

Links of interest